Quantcast

Debiopharm and Ipsen Extend Their Strategic Decapeptyl® (triptorelin) Partnership for Another 15 Years

Debiopharm and Ipsen extend and strengthen their ongoing
collaboration to ensure patient access to Decapeptyl
®
for the treatment of certain urological, gynecological and pediatric
conditions

LAUSANNE, Switzerland & PARIS–(BUSINESS WIRE)–Regulatory News:

Debiopharm (Debiopharm – www.debiopharm.com)
and Ipsen (www.ipsen.com)
today announced renewal of their Decapeptyl® agreement, which
extends and strengthens their strategic partnership through 2034 for the
development, manufacturing and distribution of Decapeptyl®
across Europe and certain Asian and African markets. Having established
their collaboration in the 1980s, this extension represents a long-term
commitment to patients, offering the benefits of Decapeptyl®
in the treatment of metastatic and non-metastatic patients with locally
advanced prostate cancer, endometriosis, uterine fibroids, central
precocious puberty and endocrine-responsive early-stage breast cancer.

Under the renewed agreement, both parties will co-develop novel
formulations and explore additional indications for other patient
populations with high unmet needs.

Our continued partnership remains critical to ensure that patients
maintain access to Decapeptyl
® therapy for their
various conditions. Furthermore, this renewed agreement represents an
opportunity to refine and refocus our collaboration by further exploring
our co-development capacity to potentially identify how Decapeptyl
®
can respond to more unmet patient needs.”

Thierry Mauvernay,
President & Delegate of the Board Group, Debiopharm

We are delighted to renew and extend this partnership with
Debiopharm. This collaboration has been – and continues to be – a
testament to our commitment to patients and our shared passion with
strategic partners.”

Ivana Magovčević-Liebisch, Executive
Vice-President, Chief Business Officer

About Decapeptyl®

Decapeptyl® (triptorelin pamoate) is an agonist
analogue of the natural gonadotropin-releasing hormone (GnRH), currently
available in three sustained-release formulations (1, 3 and 6 months).
First registered in France in 1986, triptorelin is currently marketed in
more than 80 countries, being the market leader in many territories
worldwide. The alliance between Debiopharm and Ipsen for Decapeptyl®
has successfully delivered sustained market growth with €372.6 million
total sales in 2018, representing 8.1% annual growth.

About Debiopharm

Debiopharm aims to develop innovative therapies that target high unmet
medical needs in oncology and bacterial infections. Bridging the gap
between disruptive discovery products and real-world patient reach, the
company identifies high-potential compounds for in-licensing, clinically
demonstrate their safety and efficacy and then select large
pharmaceutical commercialization partners to maximize patient access
globally. For more information on Debiopharm, visit www.debiopharm.com
and follow @DebiopharmNews at http://twitter.com/DebiopharmNews.

About Ipsen

Ipsen is a global specialty-driven biopharmaceutical group focused on
innovation and Specialty Care. The group develops and commercializes
innovative medicines in three key therapeutic areas – Oncology,
Neuroscience and Rare Diseases. Its commitment to Oncology is
exemplified through its growing portfolio of key therapies for prostate
cancer, neuroendocrine tumors, renal cell carcinoma and pancreatic
cancer. Ipsen also has a well-established Consumer Healthcare business.
With total sales over €2.2 billion in 2018, Ipsen sells more than 20
drugs in over 115 countries, with a direct commercial presence in more
than 30 countries. Ipsen’s R&D is focused on its innovative and
differentiated technological platforms located in the heart of the
leading biotechnological and life sciences hubs (Paris-Saclay, France;
Oxford, UK; Cambridge, US). The Group has about 5,700 employees
worldwide. Ipsen is listed in Paris (Euronext: IPN) and in the United
States through a Sponsored Level I American Depositary Receipt program
(ADR: IPSEY). For more information on Ipsen, visit www.ipsen.com.

Forward Looking Statement

The forward-looking statements, objectives and targets contained herein
are based on the Group’s management strategy, current views and
assumptions. Such statements involve known and unknown risks and
uncertainties that may cause actual results, performance or events to
differ materially from those anticipated herein. All of the above risks
could affect the Group’s future ability to achieve its financial
targets, which were set assuming reasonable macroeconomic conditions
based on the information available today. Use of the words “believes”,
“anticipates” and “expects” and similar expressions are intended to
identify forward-looking statements, including the Group’s expectations
regarding future events, including regulatory filings and
determinations. Moreover, the targets described in this document were
prepared without taking into account external growth assumptions and
potential future acquisitions, which may alter these parameters. These
objectives are based on data and assumptions regarded as reasonable by
the Group. These targets depend on conditions or facts likely to happen
in the future, and not exclusively on historical data. Actual results
may depart significantly from these targets given the occurrence of
certain risks and uncertainties, notably the fact that a promising
product in early development phase or clinical trial may end up never
being launched on the market or reaching its commercial targets, notably
for regulatory or competition reasons. The Group must face or might face
competition from generic products that might translate into a loss of
market share. Furthermore, the Research and Development process involves
several stages each of which involves the substantial risk that the
Group may fail to achieve its objectives and be forced to abandon its
efforts with regards to a product in which it has invested significant
sums. Therefore, the Group cannot be certain that favorable results
obtained during pre-clinical trials will be confirmed subsequently
during clinical trials, or that the results of clinical trials will be
sufficient to demonstrate the safe and effective nature of the product
concerned. There can be no guarantees a product will receive the
necessary regulatory approvals or that the product will prove to be
commercially successful. If underlying assumptions prove inaccurate or
risks or uncertainties materialize, actual results may differ materially
from those set forth in the forward-looking statements. Other risks and
uncertainties include but are not limited to, general industry
conditions and competition; general economic factors, including interest
rate and currency exchange rate fluctuations; the impact of
pharmaceutical industry regulation and health care legislation; global
trends toward health care cost containment; technological advances, new
products and patents attained by competitors; challenges inherent in new
product development, including obtaining regulatory approval; the
Group’s ability to accurately predict future market conditions;
manufacturing difficulties or delays; financial instability of
international economies and sovereign risk; dependence on the
effectiveness of the Group’s patents and other protections for
innovative products; and the exposure to litigation, including patent
litigation, and/or regulatory actions. The Group also depends on third
parties to develop and market some of its products which could
potentially generate substantial royalties; these partners could behave
in such ways which could cause damage to the Group’s activities and
financial results. The Group cannot be certain that its partners will
fulfil their obligations. It might be unable to obtain any benefit from
those agreements. A default by any of the Group’s partners could
generate lower revenues than expected. Such situations could have a
negative impact on the Group’s business, financial position or
performance. The Group expressly disclaims any obligation or undertaking
to update or revise any forward-looking statements, targets or estimates
contained in this press release to reflect any change in events,
conditions, assumptions or circumstances on which any such statements
are based, unless so required by applicable law. The Group’s business is
subject to the risk factors outlined in its registration documents filed
with the French Autorité des Marchés Financiers. The risks and
uncertainties set out are not exhaustive and the reader is advised to
refer to the Group’s 2018 Registration Document available on its website
(www.ipsen.com).

Contacts

Debiopharm Contact
Dawn Haughton
Communication Manager
[email protected]opharm.com
Tel:
+41 (0)21 321 01 11

Ipsen Contact
Christian
Marcoux
Senior Vice President, Global Communications Relations
[email protected]
Tel:
+33 (0)1 58 33 67 94

Ipsen – Financial Community
Eugenia
Litz
Vice President, Investor
[email protected]
Tel:
+44 (0) 1753 627721

Read the full article

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.